These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 32166932)

  • 1. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis.
    Sun C; Xia J
    Minerva Med; 2020 Jun; 111(3):254-265. PubMed ID: 32166932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 5. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.
    Balato A; Scala E; Balato N; Caiazzo G; Di Caprio R; Monfrecola G; Raimondo A; Lembo S; Ayala F
    Expert Opin Biol Ther; 2017 Nov; 17(11):1363-1374. PubMed ID: 28791896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of IL-17 in psoriasis.
    Malakouti M; Brown GE; Wang E; Koo J; Levin EC
    J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
    Aarts P; Dudink K; Vossen ARJV; van Straalen KR; Ardon CB; Prens EP; van der Zee HH
    Drugs; 2021 Aug; 81(12):1397-1410. PubMed ID: 34283386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
    Blauvelt A; Armstrong A; Merola JF; Strober B; de Cuyper D; Peterson L; Davies O; Stark JL; Lebwohl M
    J Am Acad Dermatol; 2024 Jul; 91(1):72-81. PubMed ID: 38447700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tildrakizumab: A Review of Phase II and III Clinical Trials.
    Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
    Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
    Shimizu T; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol Sci; 2019 Sep; 95(3):90-98. PubMed ID: 31362906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis: A STAT3-Centric View.
    Calautti E; Avalle L; Poli V
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging systemic drugs in the treatment of plaque psoriasis.
    Balogh EA; Bashyam AM; Ghamrawi RI; Feldman SR
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):89-100. PubMed ID: 32192366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
    Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
    J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
    Takamura S; Takahashi A; Inoue Y; Teraki Y
    J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ; Lebwohl MG
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.